NCT01088529View on ClinicalTrials.gov

Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Prostate Cancer
Interventions
DRUG

Abiraterone Acetate

1000 mg oral daily for 3 months followed by a prostatectomy.

DRUG

Prednisone

5 mg orally daily.

DRUG

LHRHa

LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.

Trial Locations (1)

Unknown

Houston

Sponsors
All Listed Sponsors
lead

Cougar Biotechnology, Inc.

INDUSTRY